Delamanid 相關新聞

← 返回新聞總覽


Delamanid 目前有 0 則相關新聞報導,預測適應症 20 個。

本頁整合 Delamanid 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
  • 原適應症:Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants with a body weight of...
  • 證據等級:L5
  • 預測適應症(20 個):
    • multidrug-resistant tuberculosis(99.9%)
    • tuberculosis, bovine(99.9%)
    • tuberculoma(99.9%)
    • tuberculosis, avian(99.9%)
    • inactive tuberculosis(99.9%)
    • tuberculous ascites(99.9%)
    • allergic urticaria(99.6%)
    • cutaneous tuberculosis(99.1%)
    • fascioliasis(99.0%)
    • inhalational botulism(98.9%)
    • urea cycle disorder(98.8%)
    • toxin-mediated infectious botulism(98.7%)
    • hyperamylasemia(98.6%)
    • polyclonal hyperviscosity syndrome(98.6%)
    • leishmaniasis, diffuse cutaneous(98.6%)
    • congenital analbuminemia(98.4%)
    • Clostridium infectious disease(98.2%)
    • extrapulmonary tuberculosis(98.1%)
    • blood group incompatibility(98.0%)
    • vulvovaginal candidiasis(97.8%)

查看完整藥物報告 →

相關新聞(0 則)

目前沒有相關新聞報導。當有新聞提到此藥物時,系統會自動收集並顯示在這裡。

免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.